ArticlePDF Available

Apparent Hyperpigmented Skin Blemish That Has Been Incidentally Treated with Oral Krill Oil: A Case Report

Authors:
Volume 4 | Issue 1 | 1 of 3
J Med - Clin Res & Rev; 2020
Apparent Hyperpigmented Skin Blemish That Has Been Incidentally
Treated with Oral Krill Oil: A Case Report
1Şenay Kocakoğlu: Harran University Medical Faculty Department
of Family Medicine, Şanlıurfa, Turkey.
2Ersin Akpınar: Çukurova University Medical Faculty Department
of Family Medicine, Adana, Turkey.
*Correspondence:
Ersin AKPINAR, MD, Professor of Family Medicine, Çukurova
University Family Medicine Department, Balcali, Saricam –
01330 Adana / Turkey, Tel: +90322 – 338 6060 / (Ext:3087);
+90322 – 344 3501 (Outpatient Clinics); Fax: +90322- 338
6023.
Received: 02 January 2020; Accepted: 17 January 2020
Şenay Koçakoğlu1* and Ersin Akpınar2
Journal of Medical - Clinical Research & Reviews
ISSN 2639-944XCase Report
Citation: Şenay Koçakoğlu, Ersin Akpınar. Apparent Hyperpigmented Skin Blemish That Has Been Incidentally Treated with Oral
Krill Oil: A Case Report. J Med - Clin Res & Rev. 2020; 4(1): 1-3.
ABSTRACT
Background: Krill oil is considered to be remarkable with its balanced content and its high bioavailability. There
are various studies on dierent uses and benets of krill. Astaxantin, one of the content of krill, was researched for
cosmetic benets like skin wrinkles and age spots. There are no sucient number of studies on oral krill oil use
for hyperpigmentation of the skin.
Case presentation: In this case report we present a patient who had an apparent hyperpigmented blemish on
his face and his skin appearance returned to normal after oral krill oil usage. We aimed to draw attention to the
probable cosmetic benets of krill oil on skin hyperpigmentation disorders.
Conclusion: Skin blemish on the face is a cosmetic problem that negatively aects human psychology. The
presented case preoccupies that oral krill oil can be used as an eective and non-invasive alternative treatment
way for hyperpigmented areas of the skin and performing further studies on this subject may be benecial.
Keywords
Krill oil, Hyperpigmentation, Bioavailability, Astaxanthin.
Background
Krill is a form of marine crustaceans that are quite small in size.
Natural habitat of krill is known to be Antarctic Ocean. Krill is a
remarkable natural food with its content and high bioavailability
[1,2]. American Food and Drug Administration (FDA) called krill
as "Generally Recognized as Safe (GRAS)" so krill oil can be
safely preferred as a natural food source [3].
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
which are omega 3 poly unsaturated long chain essential fatty
acids (Ω-3 PUFAs) exist in the krill [4]. These fatty acids have an
important role in human metabolism and prevention and treatment
of chronic diseases, so new sources of Ω- 3 and therefore krill are
noteworthy [5]. Astaxantin, which is one of the contents of krill
is reported to be benecial for improving hyperpigmentation [6].
Case Presentation
A 47 years old male patient admitted to our family medicine clinic
for his routine periodic controls. His physical examination and
blood test values were normal.
A review of the patient's previous recorded data showed an
apparent hyperpigmented skin blemish warning on his face until
birth. Surprisingly, this blemish was observed to disappear. When
he was questioned whether he had any treatment, it was learned
that he did not use any medication or other treatment methods, but
he had only used oral krill oil capsules 1500 mg/day. He said that
after learning about the potential benets of krill oil he decided to
use krill oil and used it during 9 months regularly.
The image of the hyperpigmented area on his face before he started
using the krill oil capsules is given in Figüre 1. The image of his
face after using krill oil is given in Figure 2.
Volume 4 | Issue 1 | 2 of 3J Med - Clin Res & Rev; 2020
Figure 1 Figure 2
Discussion
Diets with high amount of lipids are related with negatif aects on
cardiovasculary system. Krill as a source of Ω- 3 PUFA’s can be
preferred for its lower content of lipid to sh [3].
Some authors report that although bioavilability of krill sourced
EPA and DHA is claimed to be better, it is not as high as claimed.
The study on this issue by Ulven et al. showed that there is no
signicant dierence between sh and krill oil. However Maki et
al. achieved important results in favor of krill. Von Schacky also
showed in his study that bioavailability of krill-derived EPA is
superior to sh [7-9].
While sh contains only triglycerides, there are both phospholipids
and triglycerides in the content of krill. A large proportion of EPA
and DHA are attached to phospholipids in the krill and the rate of
absorption of fatty acids into the circulation and the bioavailability
of Ω-3 PUFAs are quite higher in this form [2].
The krill oil diet was shown to be benecial for lowering cholesterol
components and have positive aect on vasculary damage. Lipase
plays an important role in triglyceride metabolism. Fish products
that are in triglyceride form contain high amounts of EPA and
DHA. Their absorption requires lipase activity [8,10].
Studies performed with mice with phospholipase A2 (pPLA2)
deciency showed that PL metabolism was not aected by using
krill but that of triglycerides were aected. Krill looks superior
than sh which contains triglycerides in this respect [11].
Sampalis et al. reported that krill oil is better for improving
symptoms of premenstrual syndrome and dysmenorrhea than sh
[12].
Antioxidants have protective aect for cells by neutralizing free
radicals. Antioxidant capacity of krill oil is remarkable as a source
of astaxsantin and vitamins such vitamin A and vitamin E. It is
widely believed that astaxantin makes krill superior to sh with its
more potent antioxidant capacity by improving brain inammation
and cognitive function, cardiovasculary disease, diabetes mellitus,
and skin wrinkles and pigmentation [4,13]. Facial pigmentations
are one of the most important cosmetic problems. Age eect,
prolonged exposure to sun, cosmetic use, some drugs and diseases
can lead occurance of hyperpigmentation. There are dierent
forms of facial pigmentation such as melasma, poikiloderma and
melanosis [14]. Since improving of hyperpigmentation disorders
are known to be a dicult and long lasting process, there’s an
interest for new and eective treatment methods. A single-blind
placebo-controlled study designed with the addition of 4 mg
astaxanthin daily to the diet for six weeks showed remarkable
results. Participant’s skin exibility, wrinkles, ne lines and
moisture status were markedly improved [6,15].
Conclusion
Hyperpigmented blemished skin is a cosmetic problem that
negatively aects human psychology. Treatment with oral krill oil
seems to be an eective, safe, non invasive and easily applicable
alternative treatment strategy for apparent hyperpigmented
blemishes of the skin. Performing further studies on this subject
may be benecial.
References
1. Everson I. Introducing krill. In Everson I, ed. Krill: Biology,
Ecology and Fisheries. Malden, MA: Blackwell Sciences Ltd;
2000: vi-viii.
2. Cicero AF, Rosticci M, Morbini M, et al. Lipid-lowering and
anti-inammatory eects of omega 3 ethyl esters and krill oil
a randomized cross-over clinical trial. Archives of medical
science: AMS. 2016; 12: 507.
3. Tou JC, Jaczynski J, Chen YC. Krill for human consumption
nutritional value and potential health benets. Nutr Rev. 2007;
65: 63-77.
4. Andraka JM, Naveen S, Yannick M. Can krill oil be of use for
counteracting neuroinammatory processes induced by high
fat diet and aging. Neuroscience research. 2019.
5. Cicero AF, De Sando V, Parini A, et al. Polyunsaturated fatty
acids application in internal medicine beyond the established
cardiovascular eects. Arch Med Sci. 2012; 8: 784-793.
6. Yamashita E. Suppression of post-UVB hyperpigmentation
by topical astaxanthin from krill. Fragr. J. 1995; 14: 180-185.
7. Von Schacky C. Omega-3 Index and cardiovascular disease
prevention principle and rational. Lipid Technology. 2010; 22:
151-154.
8. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic eects of
krill oil are essentially similar to those of sh oil but at lower
dose of EPA and DHA, in healthy volunteers. Lipids. 2010;
46: 37-46.
9. Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation
increases plasma concentrations of eicosapentaenoic and
docosahexaenoic acids in overweight and obese men and
women. Nutrition research. 2009; 29: 609-615.
10. Parolini CB, Bjorndal M, Busnelli M, et al. Eect of Dietary
Components from Antarctic Krill on Atherosclerosis in
apoE-Decient Mice. Mol. Nutr. Food Res. Advanced online
publication. 2017; 61.
11. Richmond BL, Boileau AC, Zheng S, et al. Compensatory
Volume 4 | Issue 1 | 3 of 3J Med - Clin Res & Rev; 2020
© 2020 Şenay Koçakoğlu & Ersin Akpınar. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License
phospholipid digestion is required for cholesterol
absorption in pancreatic phospholipase A(2)-decient mice.
Gastroenterology. 2001; 120: 1193-1202.
12. Sampalis F, Bunea R, Pelland MF, et al. Evaluation of the
eects of Neptune krill oil on the management of premenstrual
syndrome and dysmenorrhea. Altern Med Rev. 2003; 8: 171-
179.
13. Naguib YM. Antioxidant activities of astaxanthin and related
carotenoids. J Agric Food Chem. 2000; 48: 1150-1154.
14. Perez-BA, Muñoz-Pérez MA, Camacho F. Management
of facial hyperpigmentation. American journal of clinical
dermatology. 2000; 1: 261-268.
15. Yamashita E. The Eect of a dietary supplement containing
astaxanthin on skin condition. Carotenoid Sci. 2006; 10: 91-
95.
... Krill oil is a marine-derived bioactive lipid that is extracted from oceanic krill (Euphausia superba) and commercially available in the market globally. Krill oil contains considerable amounts of long chain ω-3 polyunsaturated fatty acids, in particular eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) [2], which have numerous health benefits [3,4] and are considered as functional oils to fortify food [5], pharmaceutical [6,7] and cosmetics products [8]. Importantly, in KO, many of these fatty ω-3 acids are esterified to phospholipids, unlike standard fish oils or oils derived from terrestrial plants [9][10][11]. ...
Article
Full-text available
Raman and infrared spectroscopy, used as individual and low-level fused datasets, were evaluated to identify and quantify the presence of adulterants (palm oil, PO; ω-3 concentrates in ethyl ester, O3C and fish oil, FO) in krill oil. These datasets were qualitatively analysed with principal component analysis (PCA) and classified as adulterated or unadulterated using support vector machines (SVM). Using partial least squares regression (PLSR), it was possible to identify and quantify the adulterant present in the KO mixture. Raman spectroscopy performed better (r2 = 0.98; RMSEP = 2.3%) than IR spectroscopy (r2 = 0.91; RMSEP = 4.2%) for quantification of O3C in KO. A data fusion approach further improved the analysis with model performance for quantification of PO (r2 = 0.98; RMSEP = 2.7%) and FO (r2 = 0.76; RMSEP = 9.1%). This study demonstrates the potential use of Raman and IR spectroscopy to quantify adulterants present in KO.
Article
Full-text available
The purpose of the present study is to investigate the effects of krill oil and fish oil on serum lipids and markers of oxidative stress and inflammation and to evaluate if different molecular forms, triacylglycerol and phospholipids, of omega-3 polyunsaturated fatty acids (PUFAs) influence the plasma level of EPA and DHA differently. One hundred thirteen subjects with normal or slightly elevated total blood cholesterol and/or triglyceride levels were randomized into three groups and given either six capsules of krill oil (N = 36; 3.0 g/day, EPA + DHA = 543 mg) or three capsules of fish oil (N = 40; 1.8 g/day, EPA + DHA = 864 mg) daily for 7 weeks. A third group did not receive any supplementation and served as controls (N = 37). A significant increase in plasma EPA, DHA, and DPA was observed in the subjects supplemented with n-3 PUFAs as compared with the controls, but there were no significant differences in the changes in any of the n-3 PUFAs between the fish oil and the krill oil groups. No statistically significant differences in changes in any of the serum lipids or the markers of oxidative stress and inflammation between the study groups were observed. Krill oil and fish oil thus represent comparable dietary sources of n-3 PUFAs, even if the EPA + DHA dose in the krill oil was 62.8% of that in the fish oil. Electronic supplementary material The online version of this article (doi:10.1007/s11745-010-3490-4) contains supplementary material, which is available to authorized users.
Article
Most neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, demonstrate preceding or on-going inflammatory processes. Therefore, discovering effective means of counteracting detrimental inflammatory mediators in the brain could help alter aging-related disease onset and progression. Fish oil and marine-derived omega-3, long-chain polyunsaturated fatty acids (LC n-3) have shown promising anti-inflammatory effects both systemically and centrally. More specifically, krill oil (KO), extracted from small Antarctic crustaceans, is an alternative type of LC n-3 with reported health benefits including improvement of spatial memory and learning, memory loss, systemic inflammation and depression symptoms. Similar to the more widely studied fish oil, KO contains the long chain fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which are essential for basic brain functions. Moreover, the phospholipid bound nature of fatty acids found in KO improves bioavailability and efficiency of absorption, thus supporting the belief that KO may offer a superior method of dietary n-3 delivery. Finally, KO contains astaxanthin, an antioxidant capable of reducing potentially excessive oxidative stress and inflammation within the brain. This review will discuss the potential benefits of KO over other marine-based LC n-3 on brain inflammation and cognitive function in the context of high fat diets and aging.
Article
Scope: Antarctic krill is a great source of n-3 fatty acids and high-quality proteins. Aim of the study was to evaluate the effect of Antarctic krill components on plasma lipids and atherosclerosis development. Methods and results: Sixty apoEKO mice were divided into four groups and fed Western diet (CONTROL) or Western-like diets, differing for protein or fat content. Specifically, casein or fat in CONTROL was partially replaced by krill proteins (PRO), krill oil (KRILL OIL), or both (KRILL OIL+PRO). In KRILL OIL+PRO and KRILL OIL, cholesterol levels were significantly lower than in CONTROL group. Atherosclerosis in aorta of PRO, KRILL OIL and KRILL OIL+PRO was lower than in CONTROL, whereas, at the aortic sinus, atherosclerosis reduction was only observed in KRILL OIL. Liver steatosis, commonly present in CONTROL and PRO animals, was sporadic in KRILL OIL+PRO and KRILL OIL mice. Krill oil containing diets affected the expression of genes involved in cholesterol metabolism, mainly HMG-CoA reductase. No reduced systemic inflammation was found in all groups. Conclusion: Krill oil containing diets were able to reduce cholesterol levels, inhibit plaque development and prevent liver damage. Krill proteins also reduced atherosclerosis development through mechanisms not involving lipid metabolism. This article is protected by copyright. All rights reserved.
Conference Paper
Objective: The aim of our study was to comparatively evaluate the short-term lipid-lowering efficacy of krill oil and purified Omega 3 ethyl esters PUFAs in mildly overweight hypertriglyceridemic subjects. Design and method: This double blind, randomized clinical trial was carried out in 25 moderately hypertriglyceridemic subjects (TG = 150 - 500 mg/dL). After 4 weeks of diet and physical activity, patients were allocated to treatment with an indistinguishable pill containing Omega 3 ethyl ester PUFAs 2000 mg/die vs. Krill oil 500 mg/die to be assumed once a day. After 4 weeks of treatment, patients were asked to observe a 2-week wash-out period, and they were then assigned to the alternative treatment for a further period of 4 weeks. Results: Although both PUFA sources were able to improve TG plasma levels, esterified omega 3 PUFAs were more efficacious than Krill oil (p < 0.05). Nonetheless, only Krill oil treatment was able to significantly improve HDL-C and apoAI level, both compared to baseline (p < 0.05) and end of treatment with esterified Omega 3 PUFAs (p < 0.05) values. Both treatments were able to significantly reduce hsCRP levels from the baseline (p < 0.05), but Krill oil improved it more efficaciously than esterified omega 3 PUFAs (p < 0.05). Conclusions: Krill oil has lipid-lowering effects comparable with those obtained through a 4 time higher dose of purified Omega 3 ethyl esters PUFAs in mildly overweight hypertriglyceridemic subjects, while more efficaciously reducing hsCRP. Copyright
Article
The cosmetic effects on human skin by 4mg per day astaxanthin supplementation were demonstrated in a single blind placebo controlled study using forty-nine US healthy middle-aged women. There were significant improvements in fine lines/wrinkles and elasticity by dermatologist's assessment and in the moisture content by instrumental assessment at week 6 compares to base-line initial values.
Article
A clearer picture emerges when correlating blood levels of marine omega-3 fatty acids (eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA) to cardiovascular events than when correlating dietary intake. Therefore, the Omega-3 Index has been proposed as a novel biomarker of cardiovascular risk. The Omega-3 Index is defined as the percentage of EPA+DHA in red blood cell (RBC) fatty acids. The definition includes the analytical method, which has been standardized (HS-Omega-3 Index) similarly to other routine clinical laboratory parameters. Completed and ongoing research projects (more than 80) indicate that the HS-Omega-3 Index presently fulfils many criteria for a novel biomarker for cardiovascular risk. Because the research results are obtained with a standardized methodology, introducing the HS-Omega-3 Index into clinical routine is possible.
Article
Antarctic krill, also known as Euphausia superba, is a marine crustacean rich in both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). We tested the hypothesis that krill oil would increase plasma concentrations of EPA and DHA without adversely affecting indicators of safety, tolerability, or selected metabolic parameters. In this randomized, double-blind parallel arm trial, overweight and obese men and women (N = 76) were randomly assigned to receive double-blind capsules containing 2 g/d of krill oil, menhaden oil, or control (olive) oil for 4 weeks. Results showed that plasma EPA and DHA concentrations increased significantly more (P < .001) in the krill oil (178.4 +/- 38.7 and 90.2 +/- 40.3 micromol/L, respectively) and menhaden oil (131.8 +/- 28.0 and 149.9 +/- 30.4 micromol/L, respectively) groups than in the control group (2.9 +/- 13.8 and -1.1 +/- 32.4 micromol/L, respectively). Systolic blood pressure declined significantly more (P < .05) in the menhaden oil (-2.2 +/- 2.0 mm Hg) group than in the control group (3.3 +/- 1.5 mm Hg), and the response in the krill oil group (-0.8 +/- 1.4 mm Hg) did not differ from the other 2 treatments. Blood urea nitrogen declined in the krill oil group as compared with the menhaden oil group (P < .006). No significant differences for other safety variables were noted, including adverse events. In conclusion, 4 weeks of krill oil supplementation increased plasma EPA and DHA and was well tolerated, with no indication of adverse effects on safety parameters.
Article
The antioxidant activities of astaxanthin and related carotenoids have been measured by employing a newly developed fluorometric assay. This assay is based on 4,4-difluoro-3,5-bis(4-phenyl-1, 3-butadienyl)-4-bora-3a,4a-diaza-s-indacene (BODIPY 665/676) as an indicator; 2,2'-azobis-2,4-dimethylvaleronitrile (AMVN) as a peroxyl radical generator; and 6-hydroxy-2,5,7, 8-tetramethylchroman-2-carboxylic acid (Trolox) as a calibrator in an organic and liposomal media. By employing this assay, three categories of carotenoids were examined: namely, the hydrocarbon carotenoids lycopene, alpha-carotene, and beta-carotene; the hydroxy carotenoid lutein; and the alpha-hydroxy-ketocarotenoid astaxanthin. The relative peroxyl radical scavenging activities of Trolox, astaxanthin, alpha-tocopherol, lycopene, beta-carotene, lutein, and alpha-carotene in octane/butyronitrile (9:1, v/v) were determined to be 1.0, 1.0, 1.3, 0.5, 0.4, 0.3, and 0.2, respectively. In dioleoylphosphatidyl choline (DOPC) liposomal suspension in Tri-HCl buffer (pH 7.4 at 40 degrees C), the relative reactivities of astaxanthin, beta-carotene, alpha-tocopherol, and lutein were found to be 1.00, 0.9, 0.6, and 0.6, respectively. When BODIPY 665/676 was replaced by 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a, 4a-diaza-s-indacene-3-undecanoic acid (BODIPY 581/591 C(11)) as an indicator, astaxanthin showed the highest antioxidant activity toward peroxyl radicals. The relative reactivities of Trolox, astaxanthin, alpha-tocopherol, alpha-carotene, lutein, beta-carotene, and lycopene were determined to be 1.0, 1.3, 0.9, 0.5, 0.4, 0.2, and 0.4, respectively.
Article
Numerous studies have suggested phospholipid inhibition of dietary cholesterol absorption through the gastrointestinal tract. This study addressed the importance of luminal phospholipid hydrolysis in this process. The effect of phospholipase inhibition on cholesterol transport from intestinal lumen to the lymphatics was evaluated in lymph fistula rats. Cholesterol and phospholipid absorption efficiency in intact animals was evaluated in control and phospholipase A(2) (PLA2) gene-targeted mice. The PLA2 inhibitor FPL 67047XX retarded cholesterol absorption in a lymph fistula rat model. Under basal chow-fed dietary conditions, cholesterol absorption efficiency from a single bolus meal, and plasma lipid levels, were similar among PLA2+/+, PLA2+/-, and PLA2-/- mice. Interestingly, the nonhydrolyzable phospholipid dioleoyl ether phosphatidylcholine suppressed cholesterol absorption by 10% to 18% in mice without regard to their PLA2 genotype. When 1-palmitoyl-2-[(14)C]oleoyl-phosphatidylcholine was used as the substrate, the radiolabeled phospholipid was found to be hydrolyzed and absorbed with equal efficiency in PLA2+/+, PLA2+/-, and PLA2-/- mice. These results suggested that although phospholipid digestion in the intestinal lumen is a prerequisite for efficient cholesterol absorption, additional enzyme(s) can compensate for pancreatic PLA2 in catalyzing phospholipid digestion and facilitating cholesterol absorption in PLA2 knockout mice.